Physician profile
Michael A Lee
NPI 1255607685
$17,153.26
in general payments reported to CMS, 2019-2025
29 companies · $2,547 in 2025
The $2,547 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,312 · 2020: $448 · 2021: $1,669 · 2022: $2,033 · 2023: $2,212 · 2024: $5,930 · 2025: $2,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,963 · Consulting Fee: $2,258 · Education: $434 · Travel and Lodging: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,963.06 |
| Consulting Fee | $2,257.50 |
| Education | $434.41 |
| Travel and Lodging | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,598.94 | 2021-2025 | Sotyktu |
| Ucb, INC. | $2,958.19 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $1,425.19 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Dermavant Sciences, INC. | $1,300.94 | 2022-2024 | Vtama |
| Abbvie INC. | $1,291.13 | 2021-2025 | |
| Janssen Biotech, INC. | $1,020.89 | 2020-2025 | Tremfya |
| Pfizer INC. | $936.48 | 2020-2025 | |
| Lilly USA, LLC | $765.56 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $651.31 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $535.65 | 2022-2025 | Dupixent, Libtayo |
| Amgen INC. | $533.90 | 2019-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $378.98 | 2023-2025 | Zoryve |
| Incyte Corporation | $324.43 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $227.37 | 2021-2025 | Aklief, Nemluvio, Twyneo |
| Sanofi-Aventis U.S. LLC | $199.02 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $170.16 | 2022-2025 | Adbry |
| Vyne Pharmaceuticals INC. | $131.79 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $128.39 | 2019-2024 | Duobrii, Siliq, Cabtreo |
| Dermira, INC. | $123.51 | 2019 | |
| Prugen, INC. Pharmaceuticals | $105.05 | 2019 | |
| Genentech, INC. | $83.41 | 2022 | |
| Novartis Pharmaceuticals Corporation | $58.10 | 2023-2025 | |
| Almirall LLC | $52.08 | 2024 | Klisyri |
| Organon LLC | $40.21 | 2025 | Vtama |
| Cipher Pharmaceuticals US LLC | $37.58 | 2025 | Spinosad, Natroba |
| Hospira, INC. | $23.89 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.52 | 2023 | Spevigo |
| Tempus Ai, INC | $14.42 | 2024 | Merlin Test |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.